RNAlytics helps clinical-stage biotech companies interpret what their omics data means — for biomarker discovery, mechanism of action, and patient stratification. No overhead. Fast turnaround.
RNAlytics is an independent scientific consultancy founded by a translational immunologist and multi-omics specialist with deep expertise across the full stack — from study design through biological interpretation and clinical reporting.
We work with clinical-stage biotech and pharma companies that are generating patient omics data — bulk RNA-seq, scRNA-seq, OLINK, spatial transcriptomics, proteomics — and need rigorous, publication-quality analysis that informs real decisions: which biomarkers to advance, how a drug works, who responds and why.
We partner with clinical-stage biotech and pharmaceutical companies to provide rigorous multi-omics analysis, biomarker discovery, and translational insights that support drug development decisions.
We don't just run pipelines. Every engagement is framed around a scientific or clinical question that matters to your programme — and delivered as a clear, actionable narrative.
Identify and validate candidate biomarkers from clinical omics data (OLINK, bulk RNA-seq, scRNA-seq) to support Phase II/III endpoints and regulatory packages.
Characterise drug MoA using transcriptomics and proteomics in disease-relevant tissue, patient biopsies, or cell systems. Publication-ready outputs.
Deep immune characterisation from patient samples via scRNA-seq or snRNA-seq: cell type annotation, trajectory analysis, ligand-receptor interactions, DEG.
Tissue-resolved gene expression analysis (Visium, Xenium, MERSCOPE). Spatial niche mapping, cell-cell communication in inflamed tissue, TME characterisation.
Integrate bulk RNA-seq, OLINK, proteomics, snATAC-seq, and spatial data into a coherent biological narrative for clinical and scientific decision-making.
Ongoing strategic and analytical support — ideal for companies without in-house bioinformatics leadership. Flexible scope. Monthly billing. Rapid turnaround.
A clinical-stage biotech needed to determine whether a drug target of interest was expressed in a new disease indication — and critically, where within the tissue and in which cell types — to inform their indication expansion strategy.
RNAlytics integrated publicly available snRNA-seq, snATAC-seq, and spatial transcriptomics data to map target expression at single-cell resolution, identify the cell populations driving expression, and assess chromatin accessibility at the target locus to evaluate whether expression was likely to be pharmacologically accessible.
Findings directly informed the company's indication expansion decision and provided the biological rationale for further programme investment.
Identified relevant publicly available multi-modal dataset; rigorous quality control and cell filtering across all modalities.
Cell type annotation, clustering, and target gene expression quantified across all identified cell populations via snRNA-seq.
Regulatory element analysis at the target locus; chromatin accessibility assessed cell-type-specifically to support pharmacological rationale.
Target expression localised within tissue architecture; spatial niche analysis identified exact anatomical compartments of expression.
Integrated findings delivered as a clear scientific narrative, directly informing the indication expansion decision.
End-to-end expertise across all major omics modalities used in translational and clinical research.
| Therapeutic area | Relevant experience |
|---|---|
| Inflammatory skin disease | Psoriasis, atopic dermatitis, hidradenitis suppurativa — tissue transcriptomics and immune profiling, multiple publications |
| IBD | Mucosal transcriptomics, gut immune profiling, spatial analysis of inflamed tissue |
| Autoimmune disease | Broad — T-cell biology, Treg biology, cytokine pathway analysis, patient stratification |
| Immuno-oncology | Tumour microenvironment characterisation, immune cell infiltration, checkpoint biology |
| Fibrosis | Stromal cell profiling, fibroblast subsets, pathway analysis |
Simple, transparent, and built around your timeline.
A 30-minute conversation to understand your data, your scientific question, and what a successful outcome looks like.
A clear written proposal with defined deliverables, timeline, and fixed or hourly pricing. No surprises.
We run the analysis with regular updates. You stay involved at the biological interpretation level throughout.
Final report, figures, and code delivered in your preferred format. Post-delivery support included for questions and revisions.
We work best with organisations that have generated patient or preclinical omics data and need expert biological interpretation to inform a specific decision.
If you have patient or preclinical omics data and a scientific question that matters to your programme, we'd like to hear from you. The first call is always free and takes 30 minutes.